KURA ONCOLOGY, INC. Interest Payable, Current
KURA ONCOLOGY, INC. (KURA) had Interest Payable, Current of $24.00 thousand as of 2014-12-31, per its 10-K filed 2015-02-27.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Accrued Liabilities, Current
us-gaap:InterestPayableCurrent · last filed 2015-02-27
- 2014-12-31: Interest Payable, Current $24.00K.
- 2014-09-30: Interest Payable, Current $22.11K.
- 2014-06-30: Interest Payable, Current $20.45K.
- 2014-03-31: Interest Payable, Current $18.80K.
| Period end | Interest Payable, Current |
|---|---|
| 2014-12-31 | $24.00K 10-K · filed 2015-02-27 |
| 2014-09-30 | $22.11K 10-Q · filed 2014-11-14 |
| 2014-06-30 | $20.45K 10-Q · filed 2014-08-14 |
| 2014-03-31 | $18.80K 10-Q · filed 2014-05-15 |
| 2013-12-31 | $17.18K 10-K · filed 2015-02-27 |
| 2013-09-30 | $15.51K 10-Q · filed 2013-11-14 |
| 2013-06-30 | $13.85K 10-Q · filed 2013-08-14 |
| 2013-03-31 | $12.55K 10-Q · filed 2013-05-15 |
| 2012-12-31 | $11.30K 10-K · filed 2014-03-31 |
| 2012-09-30 | $10.01K 10-Q · filed 2012-11-14 |
| 2012-06-30 | $8.73K 10-Q · filed 2012-08-14 |
| 2012-03-31 | $7.46K 10-Q · filed 2012-05-15 |
| 2011-12-31 | $6.32K 10-K · filed 2013-03-28 |
| 2011-03-31 | $6.32K 10-Q · filed 2012-05-15 |
| 2010-12-31 | $2.72K 10-K · filed 2012-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |